ProteoGenix
Private Company
Funding information not available
Overview
ProteoGenix is a well-established, revenue-generating French biotech service provider with a core focus on antibody discovery and bioproduction. It differentiates itself by integrating proprietary AI-driven platforms for antibody humanization, affinity maturation, and developability assessment into its service offerings, aiming to accelerate client projects from research to clinic. With a broad portfolio spanning custom services for therapeutic and diagnostic developers and a large catalog of research reagents, the company operates globally, supporting both early-stage innovation and commercial product development. Its business is primarily service-based, with additional revenue from product sales.
Technology Platform
Proprietary AI-powered platform for antibody humanization, affinity maturation, and developability assessment, combined with standard phage display, hybridoma, and recombinant protein expression systems.
Opportunities
Risk Factors
Competitive Landscape
ProteoGenix competes with large, global CROs like Lonza, Thermo Fisher Scientific, and Charles River Laboratories, as well as specialized antibody service firms such as Absolute Antibody, Bio-Rad's BioLegend, and numerous regional players. Its key differentiator is the direct integration of proprietary AI tools into a full-service offering, which many larger and smaller competitors may not provide as an integrated package.